title: [Expression of Gal-3 and CD82/KAI1 proteins in non-small cell lung cancer and their clinical significance].
abstract: OBJECTIVE
  To study the expression of galectin 3 (Gal-3) and CD82/KAI1 proteins in non-small cell lung cancer (NSCLC) and the correlation between their expression and clinical significance.
  
  
  METHODS
  The expression of Gal-3 and CD82/KAI1 proteins was detected by immunohistochemistry in 160 specimens of NSCLC and 20 specimens of normal lung tissue.
  
  
  RESULTS
  The positive rates of Gal-3 and CD82/KAI1 proteins in the NSCLC were 63.8% and 37.5%, respectively, the positive rates of Gal-3 and CD82/KAI1 proteins in the normal lung tissue were 25.0% and 95.0%, respectively, and there was a significant difference between the two groups (P < 0.01). The expression of Gal-3 and CD82/KAI1 proteins was significantly correlated with the grade of tumor, lymph node metastasis, and pathological-TNM stages (all P < 0.05). Spearman analysis showed that there was a negative correlation between expressions of Gal-3 and CD82/KAI1 in NSCLC (r = -0.732, P < 0.01). Overexpression of Gal-3 and low expression of CD82/KAI1 were related to poor prognosis: the survival rate was significantly lower in the positive Gal-3 group (survival time: 23.0 ± 17.5 months) than that in the negative group (survival time: 71.6 ± 21.6 months) (P < 0.01). The survival rates of the CD82/KAI1-positive group (survival time: 72.5 ± 19.5 months) and CD82/KAI1-negative group (survival time: 21.6 ± 16.1 months) were significantly different (P < 0.01). Multivariate analysis indicated that pTNM stage and positive expression of Gal-3 and CD82/KAI1 are independent prognostic factors of NSCLC (P < 0.01).
  
  
  CONCLUSIONS
  The expression of Gal-3 and CD82/KAI1 may be related to the initiation, development and metastasis of NSCLC. Combined detection of Gal-3 and CD82/KAI1 has an important role in predicting the progression and prognosis of NSCLC.
authors.affiliation: Department of Pathology, the First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
authors.forename: Shi-wu
authors.initials: SW
authors.lastname: Wu
authors.forename: Lan
authors.initials: L
authors.lastname: Yu
authors.forename: Lei
authors.initials: L
authors.lastname: Zhou
authors.forename: Ze-nong
authors.initials: ZN
authors.lastname: Cheng
authors.forename: Yi-sheng
authors.initials: YS
authors.lastname: Tao
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism / Q000473:pathology; D005260:Female; D037502:Galectin 3 / Q000378:metabolism*; D006801:Humans; D051861:Kangai-1 Protein / Q000378:metabolism*; D008175:Lung Neoplasms / Q000378:metabolism / Q000473:pathology; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D015996:Survival Rate
chemical_list: C497688:CD82 protein, human; D037502:Galectin 3; D051861:Kangai-1 Protein